Trial Profile
Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to severely active ulcerative Colitis Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms HERICA
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2012 Actual patient number (21) added as reported by ClinicalTrials.gov.
- 17 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.